Risk factors for incident central serous retinopathy: case–control analysis of a US national managed care population

2019 ◽  
pp. bjophthalmol-2018-313050 ◽  
Author(s):  
Maggie Zhou ◽  
Sophie J Bakri ◽  
Suzann Pershing

AimTo evaluate clinical comorbidities and steroid use as risk factors for central serous retinopathy (CSR).MethodsUsing national insurance databases, we conducted a case–control study of beneficiaries with an incident diagnosis of CSR between 2007 and 2015 (n=35 492) and randomly selected controls matched on age-based and sex-based propensity scores (n=1 77 460).ResultsThe mean age (SD) of cases was 49.1 (12.2) years, and the majority (69.2%) were male. Cases were more likely to have received steroids in the past year (OR 1.14, 95% CI 1.09 to 1.19, p<0.001) and to have comorbid Cushing’s syndrome (OR 2.19, 95% CI 1.33 to 3.59, p=0.002), age-related macular degeneration (OR 5.24, 95% CI 5.00 to 5.49, p<0.001), diabetic macular oedema (OR 2.05, 95% CI 1.71 to 2.47, p<0.001) and diabetes mellitus (OR 1.44, 95% CI 1.33 to 1.56, p<0.001). Glaucoma was associated with lower odds of CSR (OR 0.54, 95% CI 0.51 to 0.56, p<0.001). Patients with other previously hypothesised risk factors (including essential hypertension, pregnancy, other autoimmune disease, sleep disorders, Helicobacter pylori infection and gastro-oesophageal reflux disease) had lower odds of CSR.ConclusionsMale middle-aged patients with recent steroid exposure were significantly more likely to develop CSR. Other risk factors include diabetes mellitus, diabetic macular oedema and age-related macular degeneration. Other previously hypothesised risk factors did not appear to confer increased risk. More research is needed to confirm and examine underlying pathophysiology.

1998 ◽  
Vol 82 (9) ◽  
pp. 996-1002 ◽  
Author(s):  
G. Chaine ◽  
A. Hullo ◽  
J. Sahel ◽  
G. Soubrane ◽  
M.-A Espinasse-Berrod ◽  
...  

Ophthalmology ◽  
2007 ◽  
Vol 114 (6) ◽  
pp. 1164-1169 ◽  
Author(s):  
Ian J. Douglas ◽  
Claire Cook ◽  
Usha Chakravarthy ◽  
Richard Hubbard ◽  
Astrid E. Fletcher ◽  
...  

2019 ◽  
Vol 103 (10) ◽  
pp. 1356-1360 ◽  
Author(s):  
Chee Wai Wong ◽  
Tina T Wong

Inhibitors of vascular endothelial growth factors are used to treat a myriad of retinal conditions, including exudative age-related macular degeneration (AMD), diabetic macular oedema (DME) and diabetic retinopathy. Although effective, long-term efficacy is limited by the need for frequent and invasive intravitreal injections. The quest for sustained action therapeutics that can be delivered to target tissue in the least invasive manner is an arduous endeavour that has ended in premature failure for several technologies in Phase II or III trials. Nevertheless, there have been promising preclinical studies, and more are on the horizon: port delivery systems for the treatment of exudative AMD have entered Phase III trials and a wide array of preclinical studies have demonstrated the potential for nanoparticles, such as liposomes, dendrimers and cell penetrating peptides to deliver therapeutics into the posterior segment via minimally invasive routes. In this review, we discuss the challenges posed by ocular barriers for drug penetration and present the recent advancements of the most pertinent drug delivery platforms with a focus on the treatment of exudative AMD and DME.


Sign in / Sign up

Export Citation Format

Share Document